The platinum-based combination chemotherapy has become one of the major modalities in anti-cancer treatment. After the first-line chemotherapy, many patients need further chemotherapy because of recurrence or metastas...The platinum-based combination chemotherapy has become one of the major modalities in anti-cancer treatment. After the first-line chemotherapy, many patients need further chemotherapy because of recurrence or metastasis. Lobaplatin is one of the third generation platinum drugs,and this article briefly reviews the clinical progression of Iobaplatin in combination chemotherapy for patients with recurrence or metastatic cancer.展开更多
Objective： The aim of the study was to observe the effects of Iobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line. Methods： The human colorectal carcinoma cell line LoVo and HR-8348 w...Objective： The aim of the study was to observe the effects of Iobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line. Methods： The human colorectal carcinoma cell line LoVo and HR-8348 were used in the present study, and different concentrations of Iobaplatin and oxaliplatin served as inhibitors. The invasion and metastasis potential were evaluated with Transwell chamber, and cell inhibition ratio was measured with MTT assay. Results： Lobaplatin and oxaliplatin could significantly decrease the abilities of invasion and metastasis of LoVo and HR-8348 as compared with the control group （P 〈 0.01）, but no difference between Iobaplatin and oxaliplatin groups was observed （P 〉 0.05）. No difference was found in the cell inhibition ratio between the Iobaplatin and oxaliplatin groups （P 〉 0.05）. Lobaplatin could inhibit colorectal carcinoma cells that oxaliplatin couldn＇t do. Conclusion： Lobaplatin is a new antitumor platinum drug and can inhibit colorectal carcinoma cells. Moreover, Iobaplatin could also inhibit colorectal carcinoma cells which are resistant to oxaliplatin.展开更多
Objective： To compare the efficacy and safety of Lobaplatin plus Etoposide （EL） and Cisplatin plus Etoposide （EP） regimens in chemonaive with extensive-stage small-cell lung cancer （SCLC）. Methods： Between Jul...Objective： To compare the efficacy and safety of Lobaplatin plus Etoposide （EL） and Cisplatin plus Etoposide （EP） regimens in chemonaive with extensive-stage small-cell lung cancer （SCLC）. Methods： Between July 2010 and July 2011, a total of 62 patients with extensive-stage small-cell lung cancer who received initial treatment in our hospital and 309 hospital of PLA. 31 patients were randomly assigned to the EL Group： Lobaplatin was given intravenously at a dose of 30 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. Another 31 patients were assigned to the EP Group： Cisplatin was given intravenously at a dose of 75 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. We evaluated the efficacy, overall response rate （ORR）, disease control rate （DCR）, the progression-free survival （PFS） and toxicity between the patients of the two groups. Results： All 62 patients were eligible. In the EL group, 2 （6.5%） patients had complete response, 20 （64.5%） patients had partial response, 5 （16.1%） patients had stable disease and 4 （12.9%） patients had progress disease. In the EP group, 2 （6.5%） patients had complete response, 22 （70.9%） patients had partial response, 4 （12.9%） patients had stable disease and 3 （9.7%） patients had progress disease. The ORR of EL and EP group were 70.9% and 77.4%, respectively, showing no significant difference （P = 0.562）. The DCR of both groups were 87% and 90%, respectively, showing no significant difference （P = 0.688）. Median PFS of patients with EL and EP regimens were 5.5 months and 5 months, respectively, showing no significant difference （P = 0.637）. Adverse events were observed in all 62 patients. Grade 1 to 4 anemia was higher in the EP group than in EL group, showing significant difference （P = 0.02）. Grade 3 and 4 thrombocytopenia was seen in 4 patients （12.9%） in EL group and 1 patient （3.2%） in EP group. Although one patient had platelet transfusion owing to Grade 4 thrombocytopenia in EL group, no significant difference （P = 0.637） were shown. The incidence of nausea/vomiting was higher in the EP group than in the EL group （96.7% vs 51.6%, P = 0.00）. Conclusien： The EL regimen is an effective and low-toxicity chemotherapy and no inferior to EP regimen in treatment response, therefore, EL regimen maybe is a good choice for patients with extensive-stage SCLC.展开更多
基金Supported by a grant from the Science and Technology Department oHebei Province(No.072761711)
文摘The platinum-based combination chemotherapy has become one of the major modalities in anti-cancer treatment. After the first-line chemotherapy, many patients need further chemotherapy because of recurrence or metastasis. Lobaplatin is one of the third generation platinum drugs,and this article briefly reviews the clinical progression of Iobaplatin in combination chemotherapy for patients with recurrence or metastatic cancer.
文摘Objective： The aim of the study was to observe the effects of Iobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line. Methods： The human colorectal carcinoma cell line LoVo and HR-8348 were used in the present study, and different concentrations of Iobaplatin and oxaliplatin served as inhibitors. The invasion and metastasis potential were evaluated with Transwell chamber, and cell inhibition ratio was measured with MTT assay. Results： Lobaplatin and oxaliplatin could significantly decrease the abilities of invasion and metastasis of LoVo and HR-8348 as compared with the control group （P 〈 0.01）, but no difference between Iobaplatin and oxaliplatin groups was observed （P 〉 0.05）. No difference was found in the cell inhibition ratio between the Iobaplatin and oxaliplatin groups （P 〉 0.05）. Lobaplatin could inhibit colorectal carcinoma cells that oxaliplatin couldn＇t do. Conclusion： Lobaplatin is a new antitumor platinum drug and can inhibit colorectal carcinoma cells. Moreover, Iobaplatin could also inhibit colorectal carcinoma cells which are resistant to oxaliplatin.
基金a grant of the Hainan Chang'an International Pharmaceutical Company Limited
文摘Objective： To compare the efficacy and safety of Lobaplatin plus Etoposide （EL） and Cisplatin plus Etoposide （EP） regimens in chemonaive with extensive-stage small-cell lung cancer （SCLC）. Methods： Between July 2010 and July 2011, a total of 62 patients with extensive-stage small-cell lung cancer who received initial treatment in our hospital and 309 hospital of PLA. 31 patients were randomly assigned to the EL Group： Lobaplatin was given intravenously at a dose of 30 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. Another 31 patients were assigned to the EP Group： Cisplatin was given intravenously at a dose of 75 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. We evaluated the efficacy, overall response rate （ORR）, disease control rate （DCR）, the progression-free survival （PFS） and toxicity between the patients of the two groups. Results： All 62 patients were eligible. In the EL group, 2 （6.5%） patients had complete response, 20 （64.5%） patients had partial response, 5 （16.1%） patients had stable disease and 4 （12.9%） patients had progress disease. In the EP group, 2 （6.5%） patients had complete response, 22 （70.9%） patients had partial response, 4 （12.9%） patients had stable disease and 3 （9.7%） patients had progress disease. The ORR of EL and EP group were 70.9% and 77.4%, respectively, showing no significant difference （P = 0.562）. The DCR of both groups were 87% and 90%, respectively, showing no significant difference （P = 0.688）. Median PFS of patients with EL and EP regimens were 5.5 months and 5 months, respectively, showing no significant difference （P = 0.637）. Adverse events were observed in all 62 patients. Grade 1 to 4 anemia was higher in the EP group than in EL group, showing significant difference （P = 0.02）. Grade 3 and 4 thrombocytopenia was seen in 4 patients （12.9%） in EL group and 1 patient （3.2%） in EP group. Although one patient had platelet transfusion owing to Grade 4 thrombocytopenia in EL group, no significant difference （P = 0.637） were shown. The incidence of nausea/vomiting was higher in the EP group than in the EL group （96.7% vs 51.6%, P = 0.00）. Conclusien： The EL regimen is an effective and low-toxicity chemotherapy and no inferior to EP regimen in treatment response, therefore, EL regimen maybe is a good choice for patients with extensive-stage SCLC.
